Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix Plc LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  -90.00 -2.2% 4,010.00 11,854 16:35:01
Bid Price Offer Price High Price Low Price Open Price
3,950.00 4,100.00 4,050.00 4,025.00 4,050.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 10.31 8.23 139.41 28.8 209
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:01 UT 2,275 4,010.00 GBX

Bioventix (BVXP) Latest News

More Bioventix News
Bioventix Investors    Bioventix Takeover Rumours

Bioventix (BVXP) Discussions and Chat

Bioventix Forums and Chat

Date Time Title Posts
17/11/202012:17Bioventix - Sheep Antibodies1,271
08/11/201613:07ShareSoc Supper in Brighton-

Add a New Thread

Bioventix (BVXP) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-11-23 16:35:014,010.002,27591,227.50UT
2020-11-23 16:12:334,003.0048019,214.40O
2020-11-23 16:12:174,075.0049019,967.50O
2020-11-23 16:10:574,075.00431,752.25O
2020-11-23 16:09:354,010.001,75070,175.00O
View all Bioventix trades in real-time

Bioventix (BVXP) Top Chat Posts

Bioventix Daily Update: Bioventix Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker BVXP. The last closing price for Bioventix was 4,100p.
Bioventix Plc has a 4 week average price of 3,990p and a 12 week average price of 3,900p.
The 1 year high share price is 4,500p while the 1 year low share price is currently 2,580p.
There are currently 5,209,333 shares in issue and the average daily traded volume is 4,722 shares. The market capitalisation of Bioventix Plc is £208,894,253.30.
sharesoc: The presentation packs and recording from our webinar with Bioventix can be found here for full members to view: hTTps:// To access the presentation, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: hTTps:// Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the presentation (and presentations on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: hTTps://
lomax99: IC:Bioventix looks to next growth phaseUsing its sheep monoclonal antibody technology, Bioventix (BVXP) creates and supplies antibodies that can locate specific cells within human blood to make clinical diagnoses. More than two-thirds of revenue is derived from royalty and licensing fees when customers employ the group's antibodies in their diagnostic products – these payments jumped by 14 per cent to £6.3m in FY2019.Used to test for vitamin D deficiency, sales of its most popular 'vitD3.5H10' antibody increased by 27 per cent to £4.3m. Whilst pricing pressures are offseting volume growth in the more mature European and US markets, the group is benefitting from customers like South Korean Boditech tapping the burgeoning Asian market. Expecting more modest Vitamin D revenue growth moving forward, the group believes its troponin assays will become the stand-out driver of sales momentum. Still in the early roll-out stage, troponin sales only amounted to £120,000 but finnCap forecasts they could reach up to £3.5m by 2025.With a typical 4 to 10-year gap between the research phase and royalty revenue coming through, the current development pipeline aims to sustain growth beyond 2025. But expansion comes at a cost; a near-30 per cent surge in research and development costs during the period served to limit operating profit growth to just 1 per cent to £7m.finnCap anticipates adjusted pre-tax profit of £7.8m and EPS of 124.8p for the June 2020 year-end, rising to £8.6m and 136.8p in FY2021.There's a lot to like about Bioventix – high operating margins, positive free cash flow and an increasing return on capital employed. But with the shares trading at a lofty 25 times forecast 2020 earnings, we'd like to see a little more evidence that troponin can drive growth before diving in. Hold.
sharesoc: Current shareholders and potential investors may be interested in our webinar with Bioventix. More information and registration here: hTTps://
stepone68: Not as lacklustre as your price prediction performance John, ho ho.
smegster: ONJohn27 Feb '20 - 11:16 - 1184 of 1243 When this warns it will halve in price ONJohn17 Mar '20 - 20:11 - 1191 of 1243 Overpriced turkey ONJohn18 Mar '20 - 17:49 - 1193 of 1243 Less tests being carried out now This will warn and drop to 12 pounds ONJohn19 Oct '20 - 07:24 - 1243 of 1243 Headline sales growth looks low on a pe of 30 But the fact there is zero liquidity saves it You have to hand it to ONJohn - atleast he doesn't give up trying
davidosh: Just to confirm that Peter Harrison will be doing a 30 minute presentation with Q&A at the next MelloMonday The Mello Monday event starts at 6pm and lasts until 9.30pm. There are nine sessions and the events are attended by 300 plus investors. The full amended programme to include this Bioventix presentation will be available on the website later today but provisionally Peter is expected to start at 6.30pm. A very popular final session of each event is the MelloBASH... The analysts, fund manager and well known investors on the panel will give their honest verdicts on whether four companies are a Buy Avoid Sell or Hold at this current juncture in the markets. Https:// All investors welcome and if you use the code MMV5 you will get a half price introductory ticket. It is quality investor content and entertainment. We had 329 investors attend last month so these are very popular. Annual passes are available and certainly a very low cost way of watching the 18 scheduled for the coming year as you will also be sent a link to the recordings to watch at your leisure and receive discounts for other investor services such as Stockopedia, ShareSoc Masterclasses etc.
pob69: Interesting to see that Peter Harrison will be presenting at the next Mello Monday, so could expect some price movements in relation to this and the impending Full Year results, so could be linked! hTTps://
pob69: With thanks to "Quality Share Surfer" on Twitter this is an extensive read and contains companies including FDEV, BVXP, and GAW The Makings of a Multibagger An Analysis of the Best Performing Stocks over the Past 5 Years The Alta Fox 2020 Summer Intern Class Project: hTTps://
melody9999: ONJohn filtered - IMV he is short a number of shares and just trying to drive the share price down - comments have no foundation. BVXP is a long term business and will suffer minimal impact from the Coronavirus
stepone68: MAybe a daft question, but can anyone tell me the BVXP share price? My spreadsheet pulls data from Yahoo Finance, which is showing 2500p, as is a portfolio watcher app I use. See hTTps:// The graph above implies 2750, as does digital look. It's not the first time Yahoo Finance has been way out - is there a reason for this? StepOne
Bioventix share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201124 04:51:36